» Articles » PMID: 28371605

MicroRNA-294 Promotes Cellular Proliferation and Motility Through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer

Overview
Specialty Biochemistry
Date 2017 Apr 4
PMID 28371605
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

In our study we examined the role of microRNA-294 (miR-294) in bladder cancer and related mechanisms. Real-time polymerase chain reaction (RT-PCR) was performed to determine the expression level of miR-294. Western blot was used to determine the expression of NRAS, mainly factors in the PI3K/AKT and JAK/STAT pathways. Cell counting kit-8 assay, clonogenic assay, wound-healing assay, transwell and flow cytometry were used to explore, respectively, cell proliferation, survival, migration, invasion, and apoptosis of bladder cancer cell line T24. The expressions of miR-294 in bladder cancer cells including J82, HT1376, T24, and SW780 were significantly increased compared to those in human bladder epithelium cells (both HCV29 and SV-HUC-1). The proliferation rate, surviving fraction, migration, and invasion of T24 cells in miR-294 mimetic transfected group were significantly increased, while they were significantly decreased by miR-294 inhibitor transfection. Moreover, miR-294 suppression could increase the apoptotic rate of T24 cells. In addition, drug resistance of T24 cells to cisplatin was increased in miR-294 mimetic-treated group, while it was decreased by miR-294 inhibitor compared to empty control. Overexpression of miR-294 could upregulate NRAS expression in T24 cells and activate PI3K/AKT and JAK/STAT pathways. We found that miR-294 expression was positively related with proliferation and motility of T24 cells. Moreover, miR-294 suppression could promote the sensitivity of T24 cells to cisplatin. We also found miR-294 could upregulate NRAS and activate the PI3K/AKT and JAK/STAT pathways in T24 cells.

Citing Articles

MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.

Li L, Zhang Y, Hu W, Zou F, Ning J, Rao T J Cell Mol Med. 2023; 27(19):2922-2936.

PMID: 37480214 PMC: 10538262. DOI: 10.1111/jcmm.17863.


Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients.

Dehghani M, Mokhtari S, Abidi H, Alipoor B, Nazer Mozaffari M, Sadeghi H Iran J Med Sci. 2023; 48(2):146-155.

PMID: 36895459 PMC: 9989244. DOI: 10.30476/IJMS.2022.92604.2391.


Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.

Tantray I, Ojha R, Sharma A Front Genet. 2023; 13:1051762.

PMID: 36685879 PMC: 9845264. DOI: 10.3389/fgene.2022.1051762.


Current treatments for non-small cell lung cancer.

Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z Front Oncol. 2022; 12:945102.

PMID: 36033435 PMC: 9403713. DOI: 10.3389/fonc.2022.945102.


A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.

Li A, Li F, Lan M, Zhang Y, Xie D, Yan M J Cancer Res Clin Oncol. 2022; 148(12):3227-3241.

PMID: 35687183 DOI: 10.1007/s00432-022-04086-y.